Rosalie Griffin, PhD
Department of Epidemiology, Division of Cancer Prevention and Population Sciences
Present Title & Affiliation
Primary Appointment
Assistant Professor, Epidemiology, Cancer Prev & Pop Sciences Division, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Lymphoma & Myeloma, Cancer Medicine Division, The University of Texas MD Anderson Cancer Center, Houston, Texas
Research Interests
Our group studies how inherited genetic variation, clonal hematopoiesis, and precancerous conditions shape the risk and progression of blood cancers. At the intersection of molecular epidemiology, computational genomics, and clinical oncology, we integrate germline and somatic genomic data with large-scale cohort, biobank, and clinical datasets to uncover early molecular events that increase cancer risk. Our goal is to translate these findings into tools for precision risk prediction and cancer prevention.
Education & Training
Degree-Granting Education
| 2020 | University of Utah, Salt Lake City, UT, US, Doctor of Philosophy in Biomedical Informatics |
| 2015 | University of Utah, Salt Lake City, UT, US, Honors Bachelor of Science in Biomedical Engineering, Magna Cum Laude |
Postgraduate Training
| 2020-2025 | Research Associate, Mayo Clinic, Rochester, MN |
Experience & Service
Extramural Institutional Committee Activities
Chair, Family and Rare Variants Working Group, International Lymphoma Epidemiology Consortium, 2025 - Present
Student Representative, Biomedical Informatics, University of Utah, 2016 - 2018
Advisor, Student Advisory Committee, University of Utah
Chair, Student Advisory Committee, Biomedical Informatics, University of Utah
Member, Admissions Committee, Biomedical Informatics, University of Utah
Honors & Awards
| Honors College Early Assurance Scholar, University of Utah | |
| Freshman Scholarship in Science and Mathematics, University of Utah | |
| Honors at Entrance Scholarship, University of Utah | |
| Academic All-American, National Collegiate Athletic Association | |
| Jack Bud Scholar-Athlete, University of Utah | |
| Most Innovative Medical Device Design, University of Utah | |
| Honors College Alumni Partnership Board Scholarship, University of Utah | |
| Richards Alumni and College of Engineering Scholarship, University of Utah | |
| Honorable Mention 800M All-American, National Collegiate Athletic Association | |
| Best Scientific Talk of Biomedical Engineering, University of Utah | |
| Postgraduate Scholarship, National Collegiate Athletic Association | |
| Student Design Challenge Finalist, American Medical Informatics Association | |
| Richard A. and Carol M. Fay Endowed Graduate Fellowship, University of Utah | |
| Distinguished Poster, American Medical Informatics Association | |
| John D. Morgan Award for Outstanding Graduate Students, Intermountain Healthcare | |
| Reed M. Gardner Fellowship, University of Utah | |
| Abstract Achievement Award, American Society of Hematology | |
| Charles J. Epstein Trainee Awards for Excellence in Human Genetics Research, American Society of Human Genetics | |
| Abstract Achievement Award, American Society of Hematology | |
| Best Poster in Hematological Malignancies, European Society for Medical Oncology |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Pre-Malignant Clonality in the Blood: Implications Across the Cancer Continuum. Invited. Precision Medicine: From Concept to Application in the Veterans Health Administration. Houston, TX.
- 2026. Clonal hematopoiesis in lymphoid malignancy risk and progression. Invited. Houston, Texas, US.
- 2025. Clonal hematopoiesis in lymphoid malignancy risk and progression. Cancer Prevention and Control Grand Rounds. Houston, Texas, US.
- 2024. Decoding Mosaic Chromosomal Alterations (mCAs) in Lymphoid Malignancies. Invited. Houston, Texas, US.
National Presentations
- 2025. Genomic diversity reveals CLL risk and prognostic factors. Invited. New York City, NY, US.
- 2024. Clonal Hematopoiesis in Lymphoid Malignancy Risk and Progression. Invited. Salt Lake City, UT, US.
- 2024. Mosaic Chromosomal Alterations: Unlocking Insights into Lymphoid Malignancy Risk & Progression. Invited. Portland, OR, US.
- 2024. Mosaic chromosomal alterations by lymphoid malignancy subtype. Invited. Stillwater, MN, US.
- 2023. Mosaic Chromosomal Alterations and Monoclonal B-cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies. Poster. San Diego, CA, US.
- 2023. Tumor Mutational Burden as a Prognostic Factor in Diffuse Large B-Cell Lymphoma. Poster. San Diego, CA, US.
- 2023. Landscape of mosaic chromosomal alterations in CLL and MBL patients. Poster. New York City, NY, US.
- 2023. Etiologic heterogeneity of genetic risk for DLBCL cell-of-origin molecular subtypes. Invited. Orlando, FL, US.
- 2021. TP53 Aberrations and Outcomes in MBL and Untreated CLL. Poster. Atlanta, GA, US.
- 2021. Deep transcriptomic profiling with quantitative measures identifies high-risk multiple myeloma. Invited, US.
- 2019. Deconstructing myeloma tumor heterogeneity: transcriptome dimension signatures. Poster. Houston, Texas, US.
- 2018. Segregation evidence from multiple extended high-risk pedigrees. Invited. Columbus, OH, US.
- 2017. Novel pedigree analysis implicates DNA repair and chromatin remodeling in MM risk. Invited. San Diego, CA, US.
- 2016. Rare germline variants in Myeloma cases overlap with candidate genes from lymphoid malignancy GWAS. Invited. Rochester, MN, US.
- 2015. Exome Sequencing in Myeloma Families. Invited. Salt Lake City, UT, US.
International Presentations
- 2026. Genome-wide profiling of mosaic chromosomal alterations identifies prognostic lesions and ancestry-associated heterogeneity in CLL. Poster. XVth International Workshop. Cologne, DE.
- 2025. Predictive value of mCAs varies by MBL status. Invited. Annual Meeting. Heidelberg, DE.
- 2024. Circulating Chromosomal Alterations in Lymphoid Malignancies. Poster. Barcelona, ES.
- 2023. Mosaic chromosomal alterations in lymphoid precancers and families. Invited. risk, clinical outcomes, and comorbidiities. Quebec, CA.
- 2023. High tumor mutational burden is protective for DLBCL survival and is associated with the NCOA1 GWAS locus. Invited. Lyon, FR.
Grant & Contract Support
| Date: | 2026 - 2030 |
| Title: | Clonal Hematopoiesis as a Biomarker for Melanoma Risk Stratification and Early Detection |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | PI |
| ID: | FP00029954 |
| Date: | 2026 - 2031 |
| Title: | Melanoma risks and outcomes in patients with clonal hematopoiesis |
| Funding Source: | NiH |
| Role: | Co-I |
| ID: | 1R01CA319796-01 |
| Date: | 2026 - 2031 |
| Title: | Cancer Prevention Research Training at MD Anderson Cancer Center |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | CA306834 |
| Date: | 2026 - 2027 |
| Title: | Long-term Assessment of SurvivorShip Outcomes (LASSO) in AYA and Young-Onset Cancers |
| Funding Source: | UT MD Anderson |
| Role: | PI |
| Date: | 2026 - 2028 |
| Title: | Melanoma Risks and Outcomes in Patients with Clonal Hematopoiesis |
| Funding Source: | Melanoma Research Alliance |
| Role: | Co-I |
| Date: | 2025 - 2028 |
| Title: | Impact of Patient Fitness and Biological Aging on Outcomes for Multiple Myeloma treated with BCMA T-Cell Redirection Therapy |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP260128 |
| Date: | 2025 - 2030 |
| Title: | Decoding Mosaic Chromosomal Alterations (mCAs) in Lymphoid Malignancy Risk and Outcomes |
| Funding Source: | NCI |
| Role: | PI |
| ID: | CA297060 |
| Date: | 2025 - 2030 |
| Title: | Recruitment of First-Time, Tenure-Track Faculty Member: Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | RR250070 |
| Date: | 2024 - 2026 |
| Title: | Prediction and Clonal Growth of Monoclonal B-Cell Lymphocytosis |
| Funding Source: | NCI |
| Role: | PI |
| ID: | CA282702 |
| Date: | 2023 - 2026 |
| Title: | Mosaic Chromosomal Alterations and MBL In Lymphoma Families and African Americans |
| Funding Source: | NCI |
| Role: | PI |
| Date: | 2020 - 2025 |
| Title: | Genetics of Common Cancers: Discovery to Implementation |
| Funding Source: | NCI |
| Role: | PI |
| ID: | F99/K00 CA234943 |
| Date: | 2015 - 2018 |
| Title: | University of Utah Biomedical Informatics Training Grant |
| Funding Source: | Institutional Grant for Research Training in Biomedical Informatics and Data Science National Library of Medicine |
| Role: | Trainee |
| ID: | LM007124 |
Selected Publications
Peer-Reviewed Articles
- Benavente, Y, Hermosa, S, Papadimitriou, N, Clay-Gilmour, AI, Brown, EE, Hofmann, JN, Rothman, N, Lan, Q, Berndt, SI, Albanes, D, Purdue, MP, Machiela, MJ, Chanock, SJ, Bhatti, P, Cozen, W, Norman, AD, Slager, S, Cerhan, JR, Rajkumar, V, Kumar, SK, Vachon, C, Novak, AJ, Habermann, TM, Link, BK, Salles, G, Ghesquières, H, Bracci, PM, Holly, EA, Griffin, R, Hildebrandt, MA, Vermeulen, R, Kolijn, PM, Hjalgrim, H, Smedby, KE, Jayasekara, H, Cheah, S, Monnereau, A, Chen, Y, Arslan, AA, Zhang, Y, Camp, NJ, Sborov, D, Osman, AE, Ziv, E, De Vivo, I, Joseph, V, Teras, LR, Patel, AV, Kane, E, Vajdic, CM, Guilloteau, A, Cocco, P, Alemany, L, Sainz, J, McKay, J, Birmann, BM, Casabonne, D. Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma. British Journal of Haematology 208(6):1942-1953, 2026. e-Pub 2026. PMID: 41873017.
- Boddicker, NJ, Shanafelt, TD, Parikh, SA, Rabe, KG, Griffin, R, Norman, AD, Yao, Y, Tian, S, Ma, T, O’Brien, D, Vallejo, BA, Hoel, MS, Lehman, SJ, Olson, JE, Hampel, PJ, Braggio, E, Patnaik, MM, Cerhan, JR, Vachon, C, Hanson, CA, Slager, S. CHIP amplifies the risk of lymphoid malignancies in individuals with monoclonal B-cell lymphocytosis (MBL). Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 41198626.
- Clay-Gilmour, AI, Camp, NJ, Wei, X, Earle, A, Norman, AD, Sinnwell, JP, Demangel, D, Griffin, R, Dumontet, C, McKay, J, Offit, K, Joseph, V, Chen, S, O’Brien, D, Rajkumar, SV, Klein, RS, Kumar, SK, Lipkin, SM, Vachon, C. Whole-Exome Sequencing-Based Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Pedigrees. Cancers 17(22), 2025. e-Pub 2025. PMID: 41300981.
- Sekar A, Griffin R, Parikh SA, Genovese G, Robinson DP, Norman AD, Olson JE, Rabe KG, Hoel MS, Boddicker NJ, Hampel PJ, Kay NE, Cerhan JR, Braggio E, Hanson CA, Vachon CM, Shanafelt TD, Ebert BL, Slager SL. Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL). Blood Cancer J 14(1):193, 2024. e-Pub 2024. PMID: 39505849.
- Wiedmeier-Nutor, JE, McCabe, CE, O’Brien, DR, Jessen, E, Bonolo de Campos, C, Boddicker, NJ, Griffin, R, Allmer, C, Rabe, KG, Cerhan, JR, Parikh, SA, Kay, NE, Yan, H, Van Dyke, DL, Slager, S, Braggio, E. Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations. Cancers 16(13), 2024. e-Pub 2024. PMID: 39001512.
- Kleinstern G, Boddicker NJ, O'Brien DR, Allmer C, Rabe KG, Norman AD, Griffin R, Yan H, Ma T, Call TG, Bruins L, Brown S, Bonolo de Campos C, Hanson CA, Leis JF, Ding W, Vachon CM, Kay NE, Oakes CC, Parker AS, Brander DM, Weinberg JB, Furman RR, Shanafelt TD, Cerhan JR, Parikh SA, Braggio E, Slager SL. Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis. Blood Adv 8(9):2118-2129, 2024. e-Pub 2024. PMID: 38359367.
- Boddicker, NJ, Parikh, SA, Norman, AD, Rabe, KG, Griffin, R, Call, TG, Robinson, DP, Olson, JE, Dispenzieri, A, Rajkumar, SV, Kumar, SK, Kay, NE, Hanson, CA, Cerhan, JR, Murray, DL, Braggio, E, Shanafelt, TD, Vachon, C, Slager, S. Relationship among three common hematological premalignant conditions. Leukemia 37(8):1719-1722, 2023. e-Pub 2023. PMID: 37147423.
- Griffin R, Wiedmeier-Nutor JE, Parikh SA, McCabe CE, O'Brien DR, Boddicker NJ, Kleinstern G, Rabe KG, Bruins L, Brown S, Bonolo de Campos C, Ding W, Leis JF, Hampel PJ, Call TG, Van Dyke DL, Kay NE, Cerhan JR, Yan H, Slager SL, Braggio E. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL. Blood Adv 7(13):3169-3179, 2023. e-Pub 2023. PMID: 36877634.
- Griffin R, Hanson HA, Avery BJ, Madsen MJ, Sborov DW, Camp NJ. Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes. Cancer Epidemiol Biomarkers Prev 32(5):708-717, 2023. e-Pub 2023. PMID: 36857768.
- Dicanio M, Giaccherini M, Clay-Gilmour A, Macauda A, Sainz J, Machiela MJ, Rybicka-Ramos M, Norman AD, Tyczynska A, Chanock SJ, Barington T, Kumar SK, Bhatti P, Cozen W, Brown EE, Suska A, Haastrup EK, Orlowski RZ, Dudzinski M, Garcia-Sanz R, Kruszewski M, Martinez-Lopez J, Beider K, Iskierka-Jazdzewska E, Pelosini M, Berndt SI, Razny M, Jamroziak K, Rajkumar SV, Jurczyszyn A, Vangsted AJ, Collado PG, Vogel U, Hofmann JN, Petrini M, Butrym A, Slager SL, Ziv E, Subocz E, Giles GG, Andersen NF, Mazur G, Watek M, Lesueur F, Hildebrandt MAT, Zawirska D, Ebbesen LH, Marques H, Gemignani F, Dumontet C, Varkonyi J, Buda G, Nagler A, Druzd-Sitek A, Wu X, Kadar K, Camp NJ, Grzasko N, Griffin R, Vachon C, Canzian F, Campa D. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. Int J Cancer 152(2):239-248, 2023. e-Pub 2023. PMID: 36082445.
- Macauda A, Clay-Gilmour A, Hielscher T, Hildebrandt MAT, Kruszewski M, Orlowski RZ, Kumar SK, Ziv E, Orciuolo E, Brown EE, Forsti A, Griffin R, Machiela MJ, Chanock SJ, Camp NJ, Rymko M, Razny M, Cozen W, Varkonyi J, Piredda C, Pelosini M, Belachew AA, Subocz E, Hemminki K, Rybicka-Ramos M, Giles GG, Milne RL, Hofmann JN, Zaucha JM, Vangsted AJ, Goldschmidt H, Rajkumar SV, Tomczak W, Sainz J, Butrym A, Watek M, Iskierka-Jazdzewska E, Buda G, Robinson DP, Jurczyszyn A, Dudzinski M, Martinez-Lopez J, Sinnwell JP, Slager SL, Jamroziak K, Reis RMV, Weinhold N, Bhatti P, Carvajal-Carmona LG, Zawirska D, Norman AD, Mazur G, Berndt SI, Campa D, Vachon CM, Canzian F. Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?. Cancer Epidemiol Biomarkers Prev 31(9):1863-1866, 2022. e-Pub 2022. PMID: 35700034.
- Macauda A, Piredda C, Clay-Gilmour AI, Sainz J, Buda G, Markiewicz M, Barington T, Ziv E, Hildebrandt MAT, Belachew AA, Varkonyi J, Prejzner W, Druzd-Sitek A, Spinelli J, Andersen NF, Hofmann JN, Dudzinski M, Martinez-Lopez J, Iskierka-Jazdzewska E, Milne RL, Mazur G, Giles GG, Ebbesen LH, Rymko M, Jamroziak K, Subocz E, Reis RM, Garcia-Sanz R, Suska A, Haastrup EK, Zawirska D, Grzasko N, Vangsted AJ, Dumontet C, Kruszewski M, Dutka M, Camp NJ, Griffin R, Tomczak W, Pelosini M, Razny M, Marques H, Abildgaard N, Watek M, Jurczyszyn A, Brown EE, Berndt S, Butrym A, Vachon CM, Norman AD, Slager SL, Gemignani F, Canzian F, Campa D. Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. Int J Cancer 149(2):327-336, 2021. e-Pub 2021. PMID: 33675538.
- Belachew AA, Wu X, Callender R, Griffin R, Orlowski RZ, Vachon CM, Camp NJ, Ziv E, Hildebrandt MAT. Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway. Cancer Epidemiol 73:101972, 2021. e-Pub 2021. PMID: 34216957.
- Griffin R, Madsen MJ, Gardner J, Sborov DW, Camp NJ. Duo Shared Genomic Segment analysis identifies a genome-wide significant risk locus at 18q21.33 in myeloma pedigrees. J Transl Genet Genom 5(2):112-123, 2021. e-Pub 2021. PMID: 34888494.
- Griffin R, Klein RJ, Vijai J, McKay JD, Clay-Gilmour A, Wei X, Madsen MJ, Sborov DW, Curtin K, Slager SL, Offit K, Vachon CM, Lipkin SM, Dumontet C, Camp NJ. Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Human Molecular Genetics 30(12):1141-1153, 2021. e-Pub 2021. PMID: 33751038.
- Taber P, Ghani P, Schiffman JD, Kohlmann W, Hess R, Chidambaram V, Kawamoto K, Griffin R, Borbolla D, Del Fiol G, Weir C. Physicians’ strategies for using family history data: having the data is not the same as using the data. JAMIA Open 3(3):378-385, 2020. PMID: 34632321.
- Clay-Gilmour AI, Hildebrandt MAT, Brown EE, Hofmann JN, Spinelli JJ, Giles GG, Cozen W, Bhatti P, Wu X, Griffin R, Belachew AA, Robinson DP, Norman AD, Sinnwell JP, Berndt SI, Rajkumar SV, Kumar SK, Chanock SJ, Machiela MJ, Milne RL, Slager SL, Camp NJ, Ziv E, Vachon CM. Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. Blood Adv 4(12):2789-2797, 2020. e-Pub 2020. PMID: 32569378.
- Wright MC, Borbolla D, Griffin R, Del Fiol G, Reese T, Nesbitt P, Segall N. Critical care information display approaches and design frameworks: A systematic review and meta-analysis. J Biomed Inform X 3, 2019. e-Pub 2019. PMID: 31423485.
- Griffin R, Wright MC, Segall N, Nesbitt P, Reese T, Borbolla D, Del Fiol G. Novel displays of patient information in critical care settings: a systematic review. J Am Med Inform Assoc 26(5):479-489, 2019. e-Pub 2019. PMID: 30865769.
- Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Griffin R, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM. Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res 78(10):2747-2759, 2018. e-Pub 2018. PMID: 29559475.
- Reese T, Segall N, Nesbitt P, Del Fiol G, Griffin R, Macpherson BC, Tonna JE, Wright MC. Patient information organization in the intensive care setting: expert knowledge elicitation with card sorting methods. JAMIA 25(8):1026-1035, 2018. e-Pub 2018. PMID: 30060091.
- Griffin R, Darlington TM, Wei X, Madsen MJ, Thomas A, Curtin K, Coon H, Rajamanickam V, Musinsky J, Jayabalan D, Atanackovic D, Rajkumar SV, Kumar S, Slager S, Middha M, Galia P, Demangel D, Salama M, Joseph V, McKay J, Offit K, Klein RJ, Lipkin SM, Dumontet C, Vachon CM, Camp NJ. Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genet 14(2):e1007111, 2018. e-Pub 2018. PMID: 29389935.
- Camp NJ, Lin WY, Bigelow A, Burghel GJ, Mosbruger TL, Parry MA, Griffin R, Rigas SH, Tai PY, Berrett K, Rajamanickam V, Cosby R, Brock IW, Jones B, Connley D, Sargent R, Wang G, Factor RE, Bernard PS, Cannon-Albright L, Knight S, Abo R, Werner TL, Reed MW, Gertz J, Cox A. Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. Cancer Res 76(7):1916-25, 2016. e-Pub 2016. PMID: 26795348.
Patient Reviews
CV information above last modified July 28, 2026